Tuttle Capital Management’s Q32 Bio QTTB Stock Holding History

Tuttle Capital Management’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,967	Closed	-$257K	–	271
2021 Q2	$257K	Buy	+1,967	New	+$245K	0.11%	222

Other funds holding QTTB

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tuttle Capital Management's QTTB Position: Q3 2021 in Review

Tuttle Capital Management sold out of Q32 Bio (QTTB) in Q3 2021, closing a stake of 1,967 shares — an estimated $257K sold.

Tuttle Capital Management first reported a position in QTTB in Q2 2021 and held it in 1 quarter. The position peaked at $257K in Q2 2021. 119 funds tracked by Wall St. Rank hold QTTB as of Q3 2021.

Tuttle Capital Management reported no remaining Q32 Bio position as of Q3 2021 after selling out during the quarter.
Tuttle Capital Management sold 1,967 Q32 Bio shares in Q3 2021, an estimated $257K.
Tuttle Capital Management first reported a position in Q32 Bio in Q2 2021 and held it in 1 quarter.
Tuttle Capital Management's Q32 Bio position peaked at $257K in Q2 2021.
119 funds tracked by Wall St. Rank held Q32 Bio as of Q3 2021.

Based on Tuttle Capital Management's 13F filing for Q3 2021, filed 20 Oct 2021.